Plaintiffs Secure $35M Settlement With Momenta Pharma in Lovenox Blood Clot Drug Antitrust Class Action

As reported by Law360 (subscription), the parties in the Lovenox/Enox blood clot drug antitrust lawsuit have announced a $35 million settlement in the class action lawsuit brought on behalf of thousands of buyers of generic Lovenox (enoxaparin) that accused the company and Sandoz Pharmaceuticals of illegally conspiring to prevent other drug companies from competing in the

2019-12-12T12:44:18+00:00December 12th, 2019|Antitrust, Firm News|

Lieff Cabraser Named Class Counsel in Now-Certified Lovenox Antitrust Class Action Against Momenta & Sandoz

Case alleges Momenta and Sandoz conspired to monopolize the production and distribution of enoxaparin, a generic version of the blood clot drug Lovenox As reported by Law360, Chief Judge Waverly D. Crenshaw, Jr. of the United States District Court for the Middle District of Tennessee has certified a class of thousands of buyers of generic

2019-09-20T19:41:40+00:00September 20th, 2019|Antitrust|